Every NAD+ Question Answered, in 16 Studies

16 referenced articles

• What Is NAD+? Structure, Role, and Why It Is Not a Peptide4 sources
• Separate Pools in Separate Compartments3 sources
• The Clock Controls NAD, and NAD Feeds Back on the Clock3 sources
• DNA Damage Draws Down the Pool3 sources
• Enzymes That Consume a Cofactor Rather Than Recycling It3 sources
• Two Products in This Catalogue, One Connected System4 sources
• Eighty Daltons Apart, and Metabolically Opposed4 sources
• NAD+ Regulatory Status4 sources
• NAD+ Storage: Different Chemistry, Different Risks3 sources
• NAD+, NMN and NR: Three Points on One Pathway4 sources
• What the Human Trials Actually Found4 sources
• NAD+ and Ageing: What Is Actually Established3 sources
• NAD+ Precursors: Nicotinamide Riboside and NMN4 sources
• The Membrane Problem: Why NAD+ Doesn't Get In3 sources
• NAD+ Molecular Structure2 sources
• Is NAD+ a Peptide? No — It Is a Dinucleotide2 sources

Open research questions

• Why is NAD+ sold in a peptide catalogue when it is not a peptide?
• Can administered NAD+ reach the inside of a cell?
• What does CD38 do to extracellular NAD+?
• Why do all the human trials use NR or NMN instead of NAD+?
• Does restoring NAD+ reverse what its decline caused?
• How is a non-peptide identity confirmed without a sequence?

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Handling checklist

• Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
• Do not apply peptide purity or net peptide content logic - neither exists here
• Store lyophilised, cold, dry and protected from light
• Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
• Be aware NAD+ and NADH are separately quantifiable oxidation states
• Identity is confirmed by mass and chromatography against a reference standard

Common mistakes

Applying peptide handling and purity guidance to NAD+

It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

Assuming administered NAD+ enters cells intact

Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

Reading precursor trial results as evidence for NAD+ itself

Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

Treating a biomarker increase as a demonstrated benefit

Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

Taking a precursor's food supplement status as evidence of efficacy

Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.